Clinical trials
Phase 2 Scleroderma, Systemic trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 26 |
| Terminated | 11 |
| Recruiting | 8 |
| Active, not recruiting | 4 |
| Suspended | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hospital for Special Surgery, New York | 4 |
| Fred Hutchinson Cancer Center | 2 |
| Lakefront Biotherapeutics NV | 2 |
| Michael Roth | 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Northwestern University | 2 |
| Pfizer | 2 |
| Sanofi | 2 |
| United Therapeutics | 2 |
| Amgen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Systemic | 52 |
| Scleroderma, Diffuse | 24 |
| Lung Diseases, Interstitial | 12 |
| Autoimmune Diseases | 4 |
| Connective Tissue Diseases | 4 |
| Raynaud Disease | 4 |
| Skin Diseases | 4 |
| Scleroderma, Limited | 3 |
| Arthritis, Rheumatoid | 2 |
| Calcinosis | 2 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.